Masahiro Endo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masahiro Endo has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Haruyasu Murakami
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
6 shared publications - Tateaki Naito
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
6 shared publications - Toshiaki Takahashi
Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
6 shared publications - Shinichiro Mori
Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Inage-ku, Chiba, Japan
5 shared publications - Akira Ono
Shizuoka Cancer Center, Shizuoka, Japan
4 shared publications - Nobuyuki Yamamoto
Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan
4 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 19 (1) , 1-7
James Chadwick (1891–1974): from the neutron discovery to neutron beams for medicine
- 17 February 2026
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 19 (1) , 1-7
Open AccessJames Chadwick (1891–1974): from the neutron discovery to neutron beams for medicine
- 26 October 2023
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 16 (4) , 443-470
Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (Part 3): Chapter 3. Clinical research, Chapter 4. Future challenges, Chapter 5. Discussion, and Conclusion
Clinical studies of ion beam therapy have been performed at the Lawrence Berkeley Laboratory (LBL), National Institute of Radiological Sciences (NIRS), Gesellschaft für Schwerionenforschung (GSI), and Deutsches Krebsforschungszentrum (DKFZ), in addition to the development of equipment, biophysical models, and treatment planning systems. Although cancers, including brain tumors and pancreatic cancer, have been treated with the Bevalac’s neon-ion beam at the LBL (where the first clinical research was conducted), insufficient results were obtained owing to the limited availability of neon-ion beams and immaturity of related technologies. However, the 184-Inch Cyclotron’s helium-ion beam yielded promising results for chordomas and chondrosarcomas at the base of the skull. Using carbon-ion beams, NIRS has conducted clinical trials for the treatment of common cancers for which radiotherapy is indicated. Because better results than X-ray therapy results have been obtained for lung, liver, pancreas, and prostate cancers, as well as pelvic recurrences of rectal cancer, the Japanese government recently approved the use of public medical insurance for carbon-ion radiotherapy, except for lung cancer. GSI obtained better results than LBL for bone and soft tissue tumors, owing to dose enhancement enabled by scanning irradiation. In addition, DKFZ compared treatment results of proton and carbon-ion radiotherapy for these tumors. This article summarizes a series of articles (Parts 1–3) and describes future issues of immune ion beam therapy and linear energy transfer optimization.
- 26 October 2023
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 16 (4) , 443-470
Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (Part 3): Chapter 3. Clinical research, Chapter 4. Future challenges, Chapter 5. Discussion, and Conclusion
Clinical studies of ion beam therapy have been performed at the Lawrence Berkeley Laboratory (LBL), National Institute of Radiological Sciences (NIRS), Gesellschaft für Schwerionenforschung (GSI), and Deutsches Krebsforschungszentrum (DKFZ), in addition to the development of equipment, biophysical models, and treatment planning systems. Although cancers, including brain tumors and pancreatic cancer, have been treated with the Bevalac’s neon-ion beam at the LBL (where the first clinical research was conducted), insufficient results were obtained owing to the limited availability of neon-ion beams and immaturity of related technologies. However, the 184-Inch Cyclotron’s helium-ion beam yielded promising results for chordomas and chondrosarcomas at the base of the skull. Using carbon-ion beams, NIRS has conducted clinical trials for the treatment of common cancers for which radiotherapy is indicated. Because better results than X-ray therapy results have been obtained for lung, liver, pancreas, and prostate cancers, as well as pelvic recurrences of rectal cancer, the Japanese government recently approved the use of public medical insurance for carbon-ion radiotherapy, except for lung cancer. GSI obtained better results than LBL for bone and soft tissue tumors, owing to dose enhancement enabled by scanning irradiation. In addition, DKFZ compared treatment results of proton and carbon-ion radiotherapy for these tumors. This article summarizes a series of articles (Parts 1–3) and describes future issues of immune ion beam therapy and linear energy transfer optimization.
- 2 May 2023
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 16 (2) , 137-159
Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (Part 2). Chapter 2. Biophysical model, treatment planning system and image guided radiotherapy
When an ion beam penetrates deeply into the body, its kinetic energy decreases, and its biological effect increases due to the change of the beam quality. To give a uniform biological effect to the target, it is necessary to reduce the absorbed dose with the depth. A bio-physical model estimating the relationship between ion beam quality and biological effect is necessary to determine the relative biological effectiveness (RBE) of the ion beam that changes with depth. For this reason, Lawrence Berkeley Laboratory, National Institute of Radiological Sciences (NIRS) and GSI have each developed their own model at the starting of the ion beam therapy. Also, NIRS developed a new model at the starting of the scanning irradiation. Although the Local Effect Model (LEM) at the GSI and the modified Microdosimetric Kinetic Model (MKM) at the NIRS, the both are currently used, can similarly predict radiation quality-induced changes in surviving fraction of cultured cell, the clinical RBE-weighted doses for the same absorbed dose are different. This is because the LEM uses X-rays as a reference for clinical RBE, whereas the modified MKM uses carbon ion beam as a reference and multiplies it by a clinical factor of 2.41. Therefore, both are converted through the absorbed dose. In PART 2, I will describe the development of such a bio-physical model, as well as the birth and evolution of a treatment planning system and image guided radiotherapy.
- 2 May 2023
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 16 (2) , 137-159
Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (Part 2). Chapter 2. Biophysical model, treatment planning system and image guided radiotherapy
When an ion beam penetrates deeply into the body, its kinetic energy decreases, and its biological effect increases due to the change of the beam quality. To give a uniform biological effect to the target, it is necessary to reduce the absorbed dose with the depth. A bio-physical model estimating the relationship between ion beam quality and biological effect is necessary to determine the relative biological effectiveness (RBE) of the ion beam that changes with depth. For this reason, Lawrence Berkeley Laboratory, National Institute of Radiological Sciences (NIRS) and GSI have each developed their own model at the starting of the ion beam therapy. Also, NIRS developed a new model at the starting of the scanning irradiation. Although the Local Effect Model (LEM) at the GSI and the modified Microdosimetric Kinetic Model (MKM) at the NIRS, the both are currently used, can similarly predict radiation quality-induced changes in surviving fraction of cultured cell, the clinical RBE-weighted doses for the same absorbed dose are different. This is because the LEM uses X-rays as a reference for clinical RBE, whereas the modified MKM uses carbon ion beam as a reference and multiplies it by a clinical factor of 2.41. Therefore, both are converted through the absorbed dose. In PART 2, I will describe the development of such a bio-physical model, as well as the birth and evolution of a treatment planning system and image guided radiotherapy.
- 8 November 2022
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 15 (4) , 271-290
Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (part 1). Introduction and Chapter 1. accelerator and beam delivery system
Radiation therapy for cancer using the Bragg peak of an ion beam has been making steady progress after being proposed by Robert Wilson in 1946. At the end of 2020, 12 dedicated treatment devices existed in operation worldwide, and approximately 40,000 patients have been treated with ion beams (mostly carbon ions). To date, ion beam therapy is superior to other treatments for rare cancers in the head and neck as well as bone and soft tissues; however, most recently, evidence submitted in Japan for the 2022 revision of public health insurance shows that ion beam therapy outperforms photon therapy for intractable common cancers such as pancreatic cancer and liver cancer. This may greatly expand its indications. Lawrence Berkeley Laboratory in the United States started research of ion beam therapy, National Institute of Radiological Sciences in Japan built the first dedicated device Heavy Ion Accelerator in Chiba and started systematic clinical research, and GSI in Germany developed the scanning irradiation method and rotating gantry for the first time. This paper presents the history and future challenges of ion beam therapy in three fields: accelerator and beam delivery system, physical/biological model and treatment planning system, and clinical research. This study is divided into three parts describing the achievements and roles of the three laboratories. In Part 1, accelerator and beam delivery system are described.
- 8 November 2022
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 15 (4) , 271-290
Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (part 1). Introduction and Chapter 1. accelerator and beam delivery system
Radiation therapy for cancer using the Bragg peak of an ion beam has been making steady progress after being proposed by Robert Wilson in 1946. At the end of 2020, 12 dedicated treatment devices existed in operation worldwide, and approximately 40,000 patients have been treated with ion beams (mostly carbon ions). To date, ion beam therapy is superior to other treatments for rare cancers in the head and neck as well as bone and soft tissues; however, most recently, evidence submitted in Japan for the 2022 revision of public health insurance shows that ion beam therapy outperforms photon therapy for intractable common cancers such as pancreatic cancer and liver cancer. This may greatly expand its indications. Lawrence Berkeley Laboratory in the United States started research of ion beam therapy, National Institute of Radiological Sciences in Japan built the first dedicated device Heavy Ion Accelerator in Chiba and started systematic clinical research, and GSI in Germany developed the scanning irradiation method and rotating gantry for the first time. This paper presents the history and future challenges of ion beam therapy in three fields: accelerator and beam delivery system, physical/biological model and treatment planning system, and clinical research. This study is divided into three parts describing the achievements and roles of the three laboratories. In Part 1, accelerator and beam delivery system are described.
- 1 January 2022
- Vol. 42 (1) , 47
[History of medical physics].
This is a review on history of medical physics in Radiological Physics and Technology published by JSRT and JSMP (https://www.jsmp.org/en/).
- 1 January 2022
- Vol. 42 (1) , 47
[History of medical physics].
This is a review on history of medical physics in Radiological Physics and Technology published by JSRT and JSMP (https://www.jsmp.org/en/).
- 2 November 2021
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 14 (4) , 345-357
History of medical physics
Medical physics began with the development of safe handling of radium, such as protecting medical personnel from radiation when radium radiation is used to treat cancer. By the end of World War II, the field of medical physics had expanded to the development of safe and reliable treatments for cancer with radiation and quantification of radiation dose, which is called dosimetry that is required to evaluate the therapeutic effect. The rapid development of nuclear technology during World War II made it possible to use large amounts of radioisotopes (RI) produced in nuclear reactors, and the medical use of RI gave birth to clinical nuclear medicine. Since knowledge and skills in radiation measurement and RI handling were required for the development and clinical use of its equipment, nuclear medicine physics was added to medical physics after the war. The invention of computed tomography (CT) in 1972 had a great impact on clinical medicine, while the development of magnetic resonance imaging (MRI) began around that time. As a result, the development of CT and MRI, as well as the study of their image characteristics, which had not necessarily been regarded as the field of medical physics before, was added to that field as radiation diagnostic physics. This review outlines the history of developments in medical physics, and touches on the first medical physicists in Europe and the United States. It also briefly explains the beginning of medical physics and the world-class medical physics achievements in Japan.
- 2 November 2021
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 14 (4) , 345-357
History of medical physics
Medical physics began with the development of safe handling of radium, such as protecting medical personnel from radiation when radium radiation is used to treat cancer. By the end of World War II, the field of medical physics had expanded to the development of safe and reliable treatments for cancer with radiation and quantification of radiation dose, which is called dosimetry that is required to evaluate the therapeutic effect. The rapid development of nuclear technology during World War II made it possible to use large amounts of radioisotopes (RI) produced in nuclear reactors, and the medical use of RI gave birth to clinical nuclear medicine. Since knowledge and skills in radiation measurement and RI handling were required for the development and clinical use of its equipment, nuclear medicine physics was added to medical physics after the war. The invention of computed tomography (CT) in 1972 had a great impact on clinical medicine, while the development of magnetic resonance imaging (MRI) began around that time. As a result, the development of CT and MRI, as well as the study of their image characteristics, which had not necessarily been regarded as the field of medical physics before, was added to that field as radiation diagnostic physics. This review outlines the history of developments in medical physics, and touches on the first medical physicists in Europe and the United States. It also briefly explains the beginning of medical physics and the world-class medical physics achievements in Japan.
- 1 April 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (3) , 666-675
Comparison of five-phase computed tomography images of type 1 autoimmune pancreatitis and pancreatic cancer: Emphasis on cases with atypical images
- 1 April 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (3) , 666-675
Comparison of five-phase computed tomography images of type 1 autoimmune pancreatitis and pancreatic cancer: Emphasis on cases with atypical images
- Open Access
- 23 October 2020
- Published by Wiley in Cancer Science
- Vol. 112 (1) , 359-368
Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
Despite the importance of accurate disease definitions for effective management and treatment decisions, there is currently no consensus on what constitutes oligometastatic non–small‐cell lung cancer (NSCLC). Predominant patterns of initial progressive disease (PD) after first‐line systemic therapy have been shown to be a substantial basis for local ablative therapy (LAT) for all disease sites in patients with oligometastatic NSCLC, suggesting that these patterns could be helpful in defining synchronous oligometastatic NSCLC. Therefore, this retrospective study aimed to propose a threshold number of metastases for synchronous oligometastatic NSCLC, based on the pattern of initial PD after first‐line systemic therapy. The cut‐off threshold number of metastases compatible with synchronous oligometastatic NSCLC was determined using receiver operating characteristic (ROC) curve analyses of PD at the initially involved sites alone. ROC analysis of 175 patients revealed that the presence of 1‐3 metastases before first‐line treatment (sensitivity, 85.9%; specificity, 97.3%; area under the curve, 0.91) was compatible with oligometastatic NSCLC, therefore we divided patients into oligometastatic NSCLC and non‐oligometastatic NSCLC groups. Multivariate logistic regression analyses revealed oligometastatic NSCLC to be the only independent predictor of PD at initially involved sites alone (odds ratio 165.7; P < .001). The median survival times in patients with oligometastatic or non‐oligometastatic NSCLC were 23.0 and 10.9 mo (hazard ratio, 0.51; P = .002), respectively. Based on these findings, we propose synchronous oligometastatic NSCLC as 1‐3 metastases in accordance with patterns of initial progression. The result of our study might be contributory to provide a common definition of synchronous oligometastatic NSCLC.
- 23 October 2020
- Published by Wiley in Cancer Science
- Vol. 112 (1) , 359-368
Open AccessProposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
Despite the importance of accurate disease definitions for effective management and treatment decisions, there is currently no consensus on what constitutes oligometastatic non–small‐cell lung cancer (NSCLC). Predominant patterns of initial progressive disease (PD) after first‐line systemic therapy have been shown to be a substantial basis for local ablative therapy (LAT) for all disease sites in patients with oligometastatic NSCLC, suggesting that these patterns could be helpful in defining synchronous oligometastatic NSCLC. Therefore, this retrospective study aimed to propose a threshold number of metastases for synchronous oligometastatic NSCLC, based on the pattern of initial PD after first‐line systemic therapy. The cut‐off threshold number of metastases compatible with synchronous oligometastatic NSCLC was determined using receiver operating characteristic (ROC) curve analyses of PD at the initially involved sites alone. ROC analysis of 175 patients revealed that the presence of 1‐3 metastases before first‐line treatment (sensitivity, 85.9%; specificity, 97.3%; area under the curve, 0.91) was compatible with oligometastatic NSCLC, therefore we divided patients into oligometastatic NSCLC and non‐oligometastatic NSCLC groups. Multivariate logistic regression analyses revealed oligometastatic NSCLC to be the only independent predictor of PD at initially involved sites alone (odds ratio 165.7; P < .001). The median survival times in patients with oligometastatic or non‐oligometastatic NSCLC were 23.0 and 10.9 mo (hazard ratio, 0.51; P = .002), respectively. Based on these findings, we propose synchronous oligometastatic NSCLC as 1‐3 metastases in accordance with patterns of initial progression. The result of our study might be contributory to provide a common definition of synchronous oligometastatic NSCLC.
- Open Access
- 10 October 2020
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 14 (1) , 1-5
Michael Goitein (1939–2016): inventor of three-dimensional planning systems with image-guided beam delivery for radiation therapy
- 10 October 2020
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 14 (1) , 1-5
Open AccessMichael Goitein (1939–2016): inventor of three-dimensional planning systems with image-guided beam delivery for radiation therapy
- Open Access
- 20 October 2017
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 11 (1) , 1-6
Robert R. Wilson (1914–2000): the first scientist to propose particle therapy—use of particle beam for cancer treatment
- 20 October 2017
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 11 (1) , 1-6
Open AccessRobert R. Wilson (1914–2000): the first scientist to propose particle therapy—use of particle beam for cancer treatment